Drug Monograph
Phenytoin
Dilantin, Phenytek
Pharmacokinetic Profile
Half-Life
22 h (range 7–42 h; concentration-dependent)
Metabolism
Hepatic (CYP2C9, CYP2C19); saturable
Protein Binding
~90% (albumin)
Bioavailability
80–95% (oral; formulation-dependent)
Volume of Distribution
0.6–0.7 L/kg
Clinical Information
Drug Class
Hydantoin anticonvulsant (Class IB antiarrhythmic)
Available Doses
30 mg, 100 mg capsules (Dilantin); 200 mg, 300 mg capsules (Phenytek); 50 mg chewable; 125 mg/5 mL suspension; 50 mg/mL injection
Route
Oral, Intravenous
Therapeutic Index
Narrow (10–20 mcg/mL)
Renal Adjustment
Monitor unbound levels
Hepatic Adjustment
Monitor unbound levels; reduce dose
Pregnancy
Category D — teratogenic
Lactation
Excreted in breast milk; use with caution
Schedule / Legal Status
Rx only (not scheduled)
Generic Available
Yes
Phenytoin Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Tonic-clonic (grand mal) seizures | Adults and pediatrics | Monotherapy or adjunctive | FDA Approved |
| Psychomotor (temporal lobe / focal) seizures | Adults and pediatrics | Monotherapy or adjunctive | FDA Approved |
| Status epilepticus (generalized tonic-clonic) | Adults and pediatrics | IV loading (after benzodiazepines) | FDA Approved |
| Seizure prophylaxis — neurosurgery | Adults and pediatrics | Prophylactic monotherapy | FDA Approved |
Phenytoin has been in continuous clinical use since 1938 and received formal FDA NDA approval in 1953, making it one of the oldest non-sedating anticonvulsants available. It remains widely used in acute settings such as status epilepticus and perioperative seizure prevention. For chronic epilepsy management, newer agents with more predictable pharmacokinetics (e.g., levetiracetam, lamotrigine) have increasingly replaced phenytoin as first-line therapy, though it remains a valid option when cost or drug availability are considerations.
Off-Label Uses
Trigeminal neuralgia: Used as second- or third-line when carbamazepine or oxcarbazepine are inadequate. Evidence quality: Low (case series, expert opinion).
Cardiac arrhythmias (digoxin-induced): Historical use as a Class IB antiarrhythmic for digitalis-related ventricular arrhythmias. Evidence quality: Low (largely replaced by other agents).
Neuropathic pain: Occasionally used when standard neuropathic pain agents fail. Evidence quality: Very Low (limited controlled data).
Phenytoin Dosing
Adult Dosing — Oral
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Epilepsy — new diagnosis, standard initiation | 100 mg TID | 300–400 mg/day | 600 mg/day | Adjust in 25–50 mg increments; wait 7–10 days between adjustments due to nonlinear kinetics Extended-release capsules only for once-daily dosing |
| Epilepsy — rapid oral loading (inpatient only) | 1 g total (400/300/300 mg at 2-hour intervals) | 300–400 mg/day starting 24 h after load | 600 mg/day | Hospital/clinic setting only; frequent level monitoring required Avoid in renal or hepatic impairment |
| Epilepsy — once-daily maintenance | 300 mg once daily | 300 mg once daily | 600 mg/day | Only with extended phenytoin sodium capsules (Dilantin); equivalent PK to divided dosing Confirm seizure-free on divided dosing before switching |
Adult Dosing — Intravenous
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Status epilepticus — IV loading | 10–20 mg/kg IV | 100 mg IV/PO q6–8h | 25–30 mg/kg total load | FDA PI: 10–15 mg/kg; AES 2016 guideline recommends 20 mg/kg for SE. Infuse at maximum 50 mg/min; ECG and BP monitoring mandatory Slower rates (25 mg/min) recommended in elderly or cardiac patients; additional 5–10 mg/kg can be given if seizures persist |
| Neurosurgical seizure prophylaxis | 10–15 mg/kg IV loading | 100 mg IV/PO q6–8h | 600 mg/day | Transition to oral as soon as clinically feasible Consider fosphenytoin if IV access is limited |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Epilepsy — oral initiation | 5 mg/kg/day in 2–3 divided doses | 4–8 mg/kg/day in divided doses | 300 mg/day | Children >6 years may need minimum adult dose (300 mg/day) Individualize based on serum levels |
| Status epilepticus — IV loading (pediatric) | 15–20 mg/kg IV | 5 mg/kg/day IV/PO in divided doses | 300 mg/day | Maximum infusion rate: 1–3 mg/kg/min or 50 mg/min (whichever is slower) Continuous cardiac monitoring required |
Clinical Pearl: Nonlinear Pharmacokinetics
Phenytoin follows saturable (Michaelis-Menten) kinetics at therapeutic concentrations. Small dose changes (e.g., 30–50 mg) can produce disproportionately large changes in serum levels. Always allow at least 7–10 days (5–7 half-lives) at any given dose before checking a steady-state trough level. The sodium salt formulation (capsules, injection) contains approximately 8% less active drug than the free acid formulation (suspension, chewable tablets) — adjust doses and monitor levels when switching formulations.
Phenytoin Pharmacology
Mechanism of Action
Phenytoin exerts its anticonvulsant effect primarily through voltage-dependent blockade of neuronal sodium channels. By preferentially binding to and stabilizing the inactivated state of these channels, it reduces the ability of neurons to fire at abnormally high frequencies. This mechanism limits the sustained repetitive firing that underlies seizure propagation without suppressing normal neuronal activity. The selectivity for rapidly firing neurons explains its clinical utility in focal and generalized tonic-clonic seizures while producing less sedation than barbiturates. Phenytoin also modulates calcium channels and may affect neurotransmitter release at the synaptic level, though sodium channel blockade remains the dominant therapeutic mechanism.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability 80–95%; Tmax 4–12 h (extended-release capsules); formulation- and diet-dependent | Absorption varies between generic formulations — monitor levels when switching brands; enteral feeding can reduce absorption |
| Distribution | Vd ~0.6–0.7 L/kg; ~90% protein-bound (albumin); crosses placenta and enters breast milk | In hypoalbuminemia, renal failure, or pregnancy, unbound fraction increases — total levels underestimate active drug; use free phenytoin levels |
| Metabolism | Hepatic via CYP2C9 (major) and CYP2C19 (minor); saturable (zero-order at therapeutic levels); major metabolite: inactive hydroxyphenytoin (p-HPPH) | Nonlinear kinetics: small dose increases produce disproportionate rises in serum concentration; CYP2C9 poor metabolizers (e.g., *2/*3, *3/*3) at risk for toxicity at standard doses |
| Elimination | t½ ~22 h (range 7–42 h; concentration-dependent, can exceed 60 h at toxic levels); <5% excreted unchanged in urine; metabolites renally eliminated | Steady state requires 7–10 days at stable doses; at toxic concentrations half-life may more than double, prolonging recovery; not significantly dialyzable |
Phenytoin Side Effects
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nystagmus | ~59% | Often first sign of rising levels; horizontal nystagmus typically appears at total levels >20 mcg/mL — dose-dependent and reversible |
| Dizziness | ~31% | Concentration-related; usually improves with dose optimization; counsel regarding driving and machinery |
| Somnolence | ~27% | Less sedating than barbiturates; more pronounced early in therapy or at supratherapeutic levels |
| Gingival hyperplasia | 30–50% | Appears within months of chronic use; severity is dose-related; emphasize meticulous oral hygiene and regular dental visits |
| Ataxia | ~18% | Cerebellar sign appearing at levels ~25–30 mcg/mL; can become irreversible with prolonged exposure to toxic levels |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 1–10% | Generally transient; consider checking levels if persistent |
| Nausea / vomiting | 1–10% | Taking with food may reduce GI irritation; more common with suspension |
| Constipation | 1–10% | Increase dietary fiber and fluid intake |
| Rash (morbilliform) | 5–10% | Usually appears within first 2 weeks; must distinguish from early signs of serious cutaneous reactions — always evaluate promptly |
| Tremor | 1–5% | Fine action tremor; concentration-dependent |
| Hirsutism / coarsening of facial features | ~5% | Cosmetic concern especially in young patients; may influence drug choice |
| Peripheral neuropathy | ~2–5% | Sensory polyneuropathy with long-term use; may be partially irreversible |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Stevens-Johnson syndrome / Toxic epidermal necrolysis (SJS/TEN) | Rare (1–6 per 10,000) | Within 28 days of initiation | Immediate discontinuation; hospitalize; dermatology consult; never rechallenge. Screen HLA-B*1502 in patients of Southeast Asian ancestry before starting. |
| DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) | Rare (1 in 1,000–10,000) | 2–8 weeks after initiation | Discontinue immediately; evaluate for organ involvement (liver, kidney, lung); systemic corticosteroids may be needed; do not rechallenge. |
| Hepatotoxicity (toxic hepatitis) | Rare | First 2–8 weeks | Discontinue phenytoin; LFT monitoring; may be part of DRESS/hypersensitivity syndrome; hepatology referral if severe. |
| Agranulocytosis / pancytopenia | Very rare | Variable (weeks to months) | Discontinue phenytoin; urgent CBC; haematology consultation; switch to alternative anticonvulsant. |
| Cardiovascular toxicity (IV administration) | Uncommon (rate-dependent) | During or immediately after infusion | Reduce infusion rate or stop; cardiac monitoring mandatory; risk increases above 50 mg/min and in elderly. |
| Cerebellar atrophy (chronic toxicity) | Rare (prolonged supratherapeutic exposure) | Months to years of toxicity | May be irreversible; stop phenytoin; neuroimaging if ataxia persists after level normalizes. |
| Lymphadenopathy / pseudolymphoma | Rare | Variable | Discontinue phenytoin; biopsy to exclude true lymphoma; symptoms typically resolve after discontinuation. |
| Osteomalacia / decreased bone mineral density | Common with chronic use | Years | Supplement vitamin D and calcium; baseline and periodic DEXA scanning in long-term users. |
Discontinuation
Discontinuation Rates
Adults
~10–15%
Top reasons: CNS effects (dizziness, ataxia), skin rash, gingival hyperplasia, cosmetic effects
Pediatrics / Adolescents
~10–20%
Top reasons: Gingival hyperplasia, hirsutism, cosmetic effects, cognitive effects — cosmetic concerns often drive switching in adolescents
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Skin rash (including SCARs concern) | 5–10% | Most rashes are benign morbilliform, but any rash must be evaluated to rule out SJS/TEN/DRESS |
| CNS adverse effects | 3–5% | Dizziness, somnolence, and ataxia — often manageable with dose reduction and level optimization |
| Gingival hyperplasia | ~3% | Cosmetically significant gingival overgrowth, particularly in younger patients |
| GI intolerance | 1–2% | Nausea and vomiting; may improve by taking with food or switching formulation |
Managing Gingival Hyperplasia
Gingival overgrowth affects up to 50% of long-term phenytoin users. Instruct patients on meticulous brushing, flossing, and antiseptic rinses. Schedule dental evaluations every 6 months. If overgrowth is severe and does not respond to improved hygiene, consider switching to an alternative anticonvulsant (e.g., levetiracetam, lamotrigine). Surgical gingivectomy may be required for established cases but recurrence is likely if phenytoin is continued.
Phenytoin Drug Interactions
Phenytoin has an exceptionally broad interaction profile driven by three pharmacokinetic properties: extensive plasma protein binding (~90% to albumin), saturable hepatic metabolism (CYP2C9/2C19), and potent induction of CYP3A4, CYP2B6, and UGT enzymes. Because of its nonlinear kinetics, even modest changes in metabolism from co-administered drugs can produce clinically significant shifts in serum phenytoin levels.
Major
Warfarin
MechanismComplex: phenytoin induces CYP3A4/2C9 (reducing warfarin effect) but also displaces warfarin from albumin (acutely increasing free warfarin); bidirectional interaction on levels
EffectUnpredictable alterations in INR; both increased and decreased anticoagulation reported
ManagementIntensify INR monitoring when initiating, adjusting, or stopping phenytoin; adjust warfarin dose based on INR trends
FDA PI
Major
Valproic Acid / Divalproex
MechanismValproate displaces phenytoin from albumin (raising free phenytoin) and inhibits its metabolism; phenytoin induces valproate glucuronidation
EffectTotal phenytoin may fall or remain stable while free (active) phenytoin rises — can cause toxicity despite apparently normal total levels; valproate levels decrease
ManagementMonitor free phenytoin levels (not total); check valproate levels concurrently; dose adjustments of both drugs often needed
FDA PI
Major
Delavirdine
MechanismPhenytoin induces CYP3A4, markedly reducing delavirdine plasma concentrations
EffectPotential loss of virologic suppression and development of NNRTI resistance
ManagementCoadministration is contraindicated per FDA PI
FDA PI
Major
Combined Oral Contraceptives
MechanismPhenytoin induces CYP3A4 and UGT enzymes, accelerating metabolism of ethinyl estradiol and progestins
EffectReduced contraceptive efficacy; breakthrough bleeding; unintended pregnancy
ManagementUse a non-enzyme-induced contraceptive method (e.g., copper IUD, depot medroxyprogesterone) or higher-dose OCP with barrier backup
FDA PI
Moderate
Carbamazepine
MechanismMutual enzyme induction; carbamazepine can increase or decrease phenytoin levels, and phenytoin generally decreases carbamazepine levels
EffectVariable changes in levels of both drugs; net direction is often unpredictable
ManagementMonitor levels of both agents closely when used together; adjust doses as guided by levels and clinical response
FDA PI
Moderate
Fluconazole / Voriconazole
MechanismAzole antifungals inhibit CYP2C9/2C19, reducing phenytoin metabolism; phenytoin induces CYP3A4, lowering azole levels
EffectElevated phenytoin levels (risk of toxicity) and reduced antifungal efficacy
ManagementMonitor phenytoin levels and adjust dose; may need increased azole dosing or alternative antifungal
FDA PI
Moderate
Dexamethasone / Corticosteroids
MechanismPhenytoin induces CYP3A4, accelerating corticosteroid metabolism
EffectReduced corticosteroid efficacy; may need higher steroid doses to achieve therapeutic effect
ManagementIncrease corticosteroid dose as clinically indicated; particularly relevant in neurosurgical patients receiving both drugs
FDA PI
Moderate
Enteral Nutrition / Antacids
MechanismContinuous tube feeds and calcium-containing antacids reduce phenytoin absorption by physical binding and altered GI pH
EffectSubtherapeutic phenytoin levels and risk of breakthrough seizures
ManagementHold tube feeds for 1–2 hours before and after phenytoin; separate antacids by at least 2 hours; monitor levels
Lexicomp
Minor
Folic Acid
MechanismFolic acid supplementation may increase phenytoin metabolism; phenytoin impairs folate absorption
EffectModest decrease in phenytoin levels possible; phenytoin can cause folate deficiency and macrocytic anemia
ManagementSupplement folic acid (especially in women of childbearing age) but monitor phenytoin levels after starting; dose adjustment rarely needed
FDA PI
Minor
Vitamin D
MechanismPhenytoin induces CYP3A4, accelerating vitamin D catabolism to inactive metabolites
EffectReduced active vitamin D → decreased calcium absorption → osteomalacia risk with long-term use
ManagementSupplement with cholecalciferol (1,000–2,000 IU/day) and calcium in long-term users; monitor 25-OH vitamin D levels
FDA PIPhenytoin Monitoring
-
Serum Phenytoin Level (Total)
Baseline, 7–10 days after initiation or any dose change, then periodically
Routine Therapeutic range: 10–20 mcg/mL (total). Obtain trough levels just before next dose. Peak levels (4–12 h post-dose for capsules) useful to assess dose-related toxicity threshold. Wait at least 5–7 half-lives after dose change before checking. -
Free (Unbound) Phenytoin Level
When total level is unreliable
Trigger-based Therapeutic range: 1–2 mcg/mL (free). Essential in patients with hypoalbuminemia, renal failure, hepatic disease, pregnancy, or when coadministered with valproic acid. The Sheiner-Tozer equation can estimate adjusted total levels but free level measurement is preferred. -
CBC with Differential
Baseline, then periodically
Routine Monitor for leukopenia, thrombocytopenia, megaloblastic anemia (folate deficiency), and rarely agranulocytosis or pancytopenia. -
Hepatic Function (LFTs)
Baseline, then periodically or if symptoms arise
Routine Phenytoin can cause toxic hepatitis, particularly within the first 2 months. LFT elevation may also signal DRESS syndrome — always evaluate in context of concurrent rash, fever, or eosinophilia. -
Serum Albumin
Baseline, then as clinically indicated
Trigger-based Low albumin increases unbound phenytoin fraction — total level may underestimate active drug exposure. Required for interpreting total levels correctly. -
Vitamin D / Bone Density
Annually (long-term therapy)
Routine Phenytoin accelerates vitamin D catabolism, contributing to osteomalacia and reduced bone mineral density. Consider DEXA scanning every 2–3 years in patients on long-term therapy, especially postmenopausal women. -
Dental Examination
Every 6 months
Routine Assess for gingival hyperplasia; reinforce oral hygiene at each visit. Early intervention with improved dental care can slow progression. -
HLA-B*1502 Screening
Before initiation (selected populations)
Trigger-based Recommended in patients of Southeast Asian ancestry (including Han Chinese, Filipino, Malaysian, South Asian Indian, and Thai descent) before starting phenytoin, due to strong association with SJS/TEN risk.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to phenytoin, other hydantoins, or any excipient in the formulation
- Prior acute hepatotoxicity attributable to phenytoin
- Coadministration with delavirdine — risk of virologic failure and NNRTI resistance (FDA PI)
- Sinus bradycardia, sino-atrial block, second- and third-degree AV block, Adams-Stokes syndrome — for IV phenytoin, due to cardiac depressant effects
Relative Contraindications (Specialist Input Recommended)
- HLA-B*1502 positive patients — strongly associated with SJS/TEN; consider alternative anticonvulsant and consult dermatology/pharmacogenomics
- CYP2C9 poor metabolizers (*3/*3 carriers) — decreased clearance leading to higher levels at standard doses; consider reduced starting dose with close level monitoring
- Severe hepatic impairment — saturable metabolism becomes more unpredictable; use free levels exclusively and consider lower doses
- Porphyria — phenytoin can exacerbate acute porphyria
Use with Caution
- Elderly patients — clearance is slightly decreased; lower or less frequent dosing may be required
- Renal impairment — altered protein binding; monitor unbound levels
- Hypoalbuminemia — increased free fraction; total level underestimates active drug
- Pregnancy — phenytoin is teratogenic (Category D); levels may decline during pregnancy due to altered PK, then rebound postpartum; monitor levels throughout and restore pre-pregnancy dose after delivery
- Patients on enteral nutrition — absorption significantly reduced by tube feeds; hold feeds around dosing
- Abrupt withdrawal — may precipitate status epilepticus; always taper gradually when discontinuing
FDA Boxed Warning
Cardiovascular Risk with Rapid IV Administration
Rapid intravenous administration of phenytoin (exceeding 50 mg/min in adults or 1–3 mg/kg/min in pediatrics) can cause severe hypotension and cardiac arrhythmias, including bradycardia, heart block, ventricular tachycardia, ventricular fibrillation, and asystole. Fatalities have been reported. Continuous ECG, blood pressure, and respiratory monitoring are essential during and after IV infusion. Slower infusion rates and post-infusion monitoring are especially important in elderly patients and those with cardiac disease.
FDA Class-Wide Regulatory Warning
Suicidality with Antiepileptic Drugs
All antiepileptic drugs, including phenytoin, are associated with an increased risk of suicidal thoughts and behavior. Pooled analyses of clinical trials showed an approximately twofold increased risk compared to placebo. Patients should be monitored for emergence of depression, suicidal ideation, or unusual behavioral changes, particularly during the first months of therapy and after dose changes.
Patient Counselling
Purpose of Therapy
Phenytoin is an anticonvulsant medication that helps prevent seizures by stabilizing electrical activity in the brain. It does not cure epilepsy but controls seizures when taken consistently every day. Maintaining steady blood levels is essential — missed doses or abrupt discontinuation can trigger breakthrough seizures.
How to Take
Take phenytoin at the same time(s) each day, preferably with food to reduce stomach upset. Swallow extended-release capsules whole — do not crush, chew, or open them. If using the suspension, shake well before each dose and use a calibrated measuring device. Do not switch between brand-name and generic formulations without consulting your prescriber, as absorption may differ between products.
Gum Overgrowth (Gingival Hyperplasia)
Tell patient
Phenytoin commonly causes gums to swell and overgrow, sometimes covering parts of the teeth. Brush teeth at least twice daily, floss daily, and use an antiseptic mouth rinse. Schedule dental check-ups every six months. Good oral hygiene can significantly reduce the severity of this effect.
Call prescriber
If gums become severely swollen, bleed easily, or interfere with eating or dental care despite diligent hygiene.
Dizziness, Drowsiness & Balance Problems
Tell patient
Dizziness, sleepiness, and unsteadiness are common, especially when starting therapy or after dose increases. Avoid driving or operating machinery until you know how phenytoin affects you. These symptoms often relate to blood levels and may improve with dose adjustment.
Call prescriber
If you develop persistent unsteadiness on your feet, double vision, slurred speech, or difficulty walking — these may indicate levels that are too high.
Skin Rash
Tell patient
A mild rash can occur early in therapy. While most rashes are harmless, phenytoin can rarely cause very serious skin reactions that require emergency treatment. Report any rash to your prescriber promptly, no matter how mild it appears.
Call prescriber
Seek immediate medical attention for any rash accompanied by fever, mouth sores, blistering, peeling skin, swollen lymph nodes, or facial swelling.
Pregnancy Planning & Contraception
Tell patient
Phenytoin can cause birth defects. If you are a woman who could become pregnant, discuss contraception with your prescriber — phenytoin reduces the effectiveness of hormonal contraceptives (the pill, patch, ring). A non-hormonal method (such as a copper IUD) is recommended. Folate supplementation is strongly advised.
Call prescriber
If you become pregnant or plan to become pregnant. Do not stop phenytoin on your own — uncontrolled seizures also pose serious risks during pregnancy.
Blood Tests & Level Monitoring
Tell patient
Regular blood tests are needed to make sure the amount of phenytoin in your blood is in the safe and effective range. Because of the way this drug is processed by your body, small dose changes can make big differences in blood levels. Keep all laboratory appointments.
Call prescriber
If you have been unable to take your medication as prescribed, if another doctor starts or stops a medication, or if you develop new symptoms that might indicate levels are too high or too low.
Mood & Behavioral Changes
Tell patient
Like all anti-seizure medications, phenytoin may slightly increase the risk of depressed mood or suicidal thoughts, particularly in the early months of therapy. Family members should also be aware of this possibility.
Call prescriber
If you experience new or worsening depression, anxiety, agitation, thoughts of self-harm, or any unusual changes in mood or behavior.
Sources
Regulatory (PI / SmPC)
- Pfizer Inc. DILANTIN (extended phenytoin sodium capsules, USP) — Full Prescribing Information. Revised 2021. FDA Label Primary source for all approved indications, dosing, contraindications, and adverse reactions for oral phenytoin.
- Pfizer Inc. DILANTIN (phenytoin sodium) Injection — Full Prescribing Information. Revised 2017. FDA Label Source for IV phenytoin dosing, cardiovascular boxed warning, infusion rate limits, and injection-specific adverse effects.
- Pfizer Inc. CEREBYX (fosphenytoin sodium) — Full Prescribing Information. Revised 2024. Pfizer Labeling Reference for fosphenytoin adverse reaction incidence data (Table 4) used to derive phenytoin-equivalent side effect rates in IV settings.
Key Clinical Trials / Systematic Reviews
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000-1015. doi:10.1016/S0140-6736(07)60460-7 Landmark pragmatic trial comparing first-line ASMs for focal epilepsy — contextualizes phenytoin’s declining use as first-line agent.
- Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48 AES guideline establishing phenytoin/fosphenytoin as second-line therapy for status epilepticus after benzodiazepine failure.
Guidelines
- Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I and II: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the AAN and the AES. Neurology. 2018;91(2):74-81. doi:10.1212/WNL.0000000000005756 AAN/AES practice guideline comparing newer anticonvulsants to phenytoin — supports phenytoin’s non-inferiority but highlights tolerability concerns.
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE Guideline NG217. Updated 2024. NICE NG217 UK clinical guideline positioning phenytoin as a second- or third-line option due to side effect profile and drug interactions.
Mechanistic / Basic Science
- Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5(7):553-564. doi:10.1038/nrn1430 Comprehensive review of anticonvulsant mechanisms including phenytoin’s voltage-dependent sodium channel blockade.
- Serafini A, Lukas RV, Engel J Jr. Phenytoin-induced gingival overgrowth: molecular and inflammatory features — a review. Mediators Inflamm. 2012;2012:502843. doi:10.1155/2012/502843 Mechanistic review of phenytoin-induced gingival hyperplasia — fibroblast activation, collagen accumulation, and inflammatory pathways.
Pharmacokinetics / Special Populations
- Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet. 1979;4(3):153-169. doi:10.2165/00003088-197904030-00001 Foundational PK study defining phenytoin’s nonlinear kinetics, protein binding, and dose-concentration relationships.
- Ahn JE, Cloyd JC, Brundage RC, et al. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. Neurology. 2008;71(1):38-43. doi:10.1212/01.wnl.0000316392.55158.5f Population PK study showing mean elimination half-life of ~40 hours at steady state — longer than traditionally cited, supporting once-daily dosing feasibility.
- Gugler R, Manion CV, Azarnoff DL. Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther. 1976;19(2):135-142. doi:10.1002/cpt1976192135 Key study demonstrating oral bioavailability of 57–86% with significant inter-individual variability, emphasizing the need for therapeutic drug monitoring.
- Leppik IE. Issues in the treatment of epilepsy in the elderly. Epilepsia. 2001;42(Suppl 4):28-33. doi:10.1046/j.1528-1157.2001.0420s4028.x Discusses altered phenytoin pharmacokinetics in elderly patients, including reduced clearance and increased sensitivity to adverse effects.